U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07425639) titled 'ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo(R), an Omalizumab Biosimilar' on Feb. 16.
Brief Summary: ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the framework of a shared medical decision, to switch them to OMLYCLO(R). The primary objective of this study is to evaluate the maintenance of this control and/or clinical remission 12 months after initiation of the biosimilar, and subsequently, patient satisfaction at 6 and 12 months.
Study St...